ArticleJournal for immunotherapy of cancer2026
IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OSA) is the most common primary malignant bone tumor in children and adolescents, while no further improvement in survival has been achieved in the past few decades. Microwave ablation (MWA) is an emerging thermal therapy to ablate malignant bone tumors that induces antitumor immunity, while intrinsic mechanisms remain elusive. This study uncovered that MWA treatment promoted interleukin (IL)-18 expression and enhanced the dendritic cell (DC) functions, as well as CD8
methodsMWA treated OSA was co-cultured with bone marrow dendritic cells (BMDC) in vitro. RNA-sequencing was performed to analyze the intrinsic mechanism of BMDC after stimulated with MWA treated OSA. Mouse model of primary osteosarcoma of the femur was established for in vivo immune response evaluation, and this model was used to measure the additive tumor eradication of IL-18 and anti-PD-1 combination therapy.
resultsMWA promoted the activation, antigen uptake and antigen cross-presentation of BMDCs. Mouse models demonstrated that MWA treatment could elevate the proportion of CD8
conclusionsOur study demonstrated a critical role of IL-18-mediated signaling in the induction of protective immune responses against OSA, which provided a novel mechanism to the explanation of MWA-induced immune activation, and IL-18 cytokine treatment could be considered a feasible, effective therapeutic approach for OSA in the clinic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.